The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

Abstract
Objective: To evaluate the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (SPMS) within the Russian cohort of the EXPAND study.

Materials and Methods: The analysis included 94 SPMS patients from Russia, of whom 63 received siponimod and 31 were assigned to a placebo group. The primary endpoint was the time to 3-month confirmed disability progression (3m-CDP), along with assessments of other clinical and radiological outcomes.

Results: Siponimod treatment resulted in a 54% reduction in the risk of 3m-CDP compared to placebo (p=0.0334). Secondary endpoints further demonstrated the superiority of siponimod over placebo. Mild adverse events, including liver function abnormalities and arterial hypertension, were more frequently observed in the siponimod group; however, no participants discontinued the study due to adverse events.

Conclusion: Siponimod significantly reduced the risk of disability BAF312 progression in SPMS patients from the Russian population and exhibited a favorable safety profile.